

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

TRIPEP.023AUS2

APPLICATION NO.

09/929,955

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT

Sallberg et al.

FILING DATE

August 15, 2001

GROUP

1648

SHEET 1 OF 3

SEP 10 2003

TECH CENTER 1601/2900

RECEIVED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
BCL	1.	4,950,647	08/21/90	Robins et al.	-	-	
	2.	5,350,671	09/27/94	Houghton et al.	-	-	
	3.	5,372,928	12/13/94	Miyamura et al.	-	-	
	4.	5,670,152	09/23/97	Weiner et al.	-	-	
	5.	5,670,153	09/23/97	Weiner et al.	-	-	
	6.	5,683,864	11/04/97	Houghton et al.	-	-	
	7.	5,712,145	01/27/98	Houghton et al.	-	-	
	8.	5,728,520	03/17/98	Weiner et al.	-	-	
	9.	5,756,312	03/26/98	Weiner et al.	-	-	
	10	5,767,097	06/16/98	Tam	-	-	
	11	5,856,437	01/05/99	Miyamura et al.	-	-	
	12	5,871,903	02/16/99	Miyamura et al.	-	-	
	13	5,942,234	08/24/99	Ralston et al.	-	-	
	14	5,989,905	11/23/99	Houghton et al.	-	-	
	15	6,060,068	05/09/00	Doyle et al.	-	-	
	16	6,063,772	05/16/00	Tam	-	-	
	17	6,071,693	06/06/00	Cha et al.	-	-	
	18	6,190,864	02/20/01	Cha et al.	-	-	
	19	6,194,140	02/27/01	Houghton et al.	-	-	
	20	6,214,583	04/10/01	Cha et al.	-	-	
	21	6,541,011	04/01/03	Punnonen et al.	-	-	
	22	6,555,114	04/29/03	Leroux-Roels et al.	-	-	
	23	2003/0044774	03/06/03	Valenzuela et al.	-	-	
	24	2003/0064360	04/03/03	Maertens et al.	-	-	

EXAMINER

Baoguan L.

DATE CONSIDERED

02/20/2004

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.


RECEIVED
SEP 10 2003
TECH CENTER 1000/2000

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. TRIPEP.023AUS2	APPLICATION NO. 09/929,955
	APPLICANT Sallberg et al.	
	FILING DATE August 15, 2001	GROUP 1648

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
BOL	25	WO 96/28162	09/19/96	WIPO	-	-		
	26	WO 97/26883	07/31/97	WIPO	-	-		
	27	WO 98/16184	04/23/98	WIPO	-	-		
	28	WO 98/16186	04/23/98	WIPO	-	-		
	29	WO 98/30223	07/16/98	WIPO	-	-		
	30	WO 00/44388	08/03/00	WIPO	-	-		

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
BOL	31	AASLD Abstracts 940, "Hepatitis C Virus NS5A Sequence Configuration does not Predict Response to Induction Interferon Plus Ribavirin," <i>Hepatology</i> , p. 394A (2000).
	32	Abregnani et al., "Perspectives for a vaccine against hepatitis C virus," <i>Journal of Hepatology</i> , 31: (suppl. 1):259-263 (1999).
	33	Bartenschlager et al., "Substrate Determinants for Cleavage in cis and in trans by the Hepatitis C Virus NS3 Proteinase," <i>Journal of Virology</i> , pp. 198 - 205, (1995).
	34	Chiang et al., "Enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response by ribavirin correlates with the increased level of IL-2," <i>Vaccine Strategies Against Microbial Pathogens</i> , 42.11-42.16, p. A949 (date unknown).
	35	Cotonat et al., "Pilot Study of Combination Therapy with Ribavirin and Interferon Alfa for the Retreatment of Chronic Hepatitis B e Antibody-Positive Patients," <i>Hepatology</i> , 31(2):502-506 (2000).
	36	Encke et al., "Genetic Immunization Generates Cellular and Humoral Immune Responses Against the Nonstructural Proteins of the Hepatitis C Virus in a Murine Model", <i>Journal of Immunology</i> , 161:4917-4923 (1998).
	37	Fang et al., "Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level," <i>Journal of Hepatology</i> , 33(5):791-798 (2000).
	38	Grakoui et al., "A second hepatitis C virus-encoded proteinase," <i>Proc. Natl. Acad. Sci USA</i> , 90:10583-10587, (1993).
	39	Hsu et al., "Prospects for a Hepatitis C Virus Vaccine", <i>Clin Liver Dis</i> , 3(4):901-915 (1999).
	40	Kumar et al., "Sequence, expression and reconstitution of an HCV genome from a British isolate derived from a single blood donation," <i>Journal of Viral Hepatitis</i> , 7:459-465 (2000).
	41	Memar O. et al., "Antiviral Agents in Dermatology; Current Status and Future Prospects," <i>Internation Journal of Dermatology</i> , 34(9):597-606 (1995).
	42	Proust B. et al., "Two Successive Hepatitis C Virus Infections in an Intravenous Drug User," <i>Journal of Clinical Microbiology</i> , 38(8):3125-3127 (2000).
	43	Ramasamy et al., "Monocyclic L-Nucleosides with Type 1 Cytokine-Inducing Activity," <i>Journal of Medicinal Chemistry</i> , 43(5):1019-1028 (2000).
	44	Schulof R. S., "Clinical, Virologic, and Immunologic Effects of Combination Therapy with Ribavirin and Isoprinosine in HIV-Infected Homosexual Men," <i>Journal of Acquired Immune Deficiency Syndromes</i> , 3(5):485-492 (1990).

EXAMINER	Bao Qun Li	DATE CONSIDERED	02/20/04
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			



FORM PT 1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

SEP 08 2003

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

ATTY. DOCKET NO.

TRIPEP.023AUS2

APPLICATION NO.

09/929,955

APPLICANT

Salberg et al.

FILING DATE

August 15, 2001

GROUP

1648

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
45	Spector et al., "The Antiviral Effect of Zidovudine and Ribavirin in Clinical Trials and the Use of p24 Antigen Levels as a Virologic Marker," <i>Journal of Infectious Diseases</i> , 159(5):822-828 (1989).
46	Tam et al., "Ribavirin Polarizes Human T Cell Responses Towards a Type 1 Cytokine Profile," <i>Journal of Hepatology</i> , 30(3):376-382 (1999) (ABSTRACT).
47	Tam et al., "The Immunomodulatory effects of ribavirin: Recent findings," <i>International Antiviral News</i> , 7/6:99 - 100 (1999).
48	Walsh et al., "Update on chronic viral hepatitis", <i>Postgrad Medical Journal</i> , 77(910):498-505 (2001).
49	Wang et al., "Synthesis and Cytokine Modulation Properties of Pyrrolo[2,3-d]-4-pyrimidone Nucleosides," <i>J. Med. Chem.</i> , 43(13):2566-2574 (2000).
50	http://www.msi.com/life/products/cerius2/modules/analogbuilder.html , C2Analog Builder, July 6, 2000.
51	Zhang et al., "Interferon- α Treatment Induces Delayed CD4 Proliferative Responses to the Hepatitis C Virus Nonstructural Protein 3 Regardless of the Outcome of Therapy," <i>The Journal of Infectious Diseases</i> , 175:1294-1301 (1997).

S:\DOCS\IES\FIESF-7006.DOC
082203

EXAMINER	<i>Daigun Li</i>	DATE CONSIDERED	<i>02/20/2004</i>
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			